Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure, Inc. (XCUR) furnished a press release on August 8, 2025 announcing its financial and operational results for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report on Form 8-K. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished and explicitly is not to be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference into registration statements except by specific reference.
This filing does not include the text of the earnings release or any financial tables within the 8-K itself; it confirms only that results were announced and that the press release is attached as an exhibit to the report.
Exicure, Inc. (Nasdaq: XCUR) filed its Form 10-Q for the quarter ended March 31, 2025. The filing confirms that the company remains a non-accelerated filer and smaller reporting company and is not a shell company. All required SEC reports and interactive data files have been submitted on time over the past 12 months. As of June 23 2025, the company had 6,317,793 common shares outstanding.
The document contains the standard sections—unaudited balance sheet, income statement, cash-flow statement, changes in stockholders’ equity, MD&A, risk factors and legal proceedings—yet the excerpt provided does not include actual financial figures or narrative discussion. Therefore, no assessment can be made regarding revenue, expenses, cash position, or profitability for the period.
Key structural disclosures gleaned from the excerpt:
- Headquarters: 400 Seaport Court, Suite 102, Redwood City, CA 94063; phone (847) 673-1700.
- Securities registered: Common Stock, $0.0001 par, trading symbol XCUR on Nasdaq.
- Table of contents shows Management’s Discussion begins on page 27 and Risk Factors on page 38, indicating extensive narrative sections.
- The cautionary note reiterates that forward-looking statements are subject to material risks, with reference to the detailed risk factors section.
Material information such as cash burn, R&D spend, and operating loss is not present in the excerpt. Investors will need to consult the full filing to evaluate liquidity runway, milestone obligations, and any updates on ongoing collaborations or litigation.
Exicure, Inc. (Nasdaq: XCUR) filed a Form 8-K dated June 27, 2025 to furnish its financial and operational results for the quarter ended March 31, 2025. The disclosure falls under Item 2.02 – Results of Operations and Financial Condition and simply states that a detailed press release is attached as Exhibit 99.1. Because the information is "furnished" rather than "filed," it is not subject to Section 18 liability and will not be incorporated by reference unless explicitly cited in a future registration statement.
No revenue, earnings, cash-flow figures or guidance appear in the 8-K text provided, and no additional items such as material transactions or strategic updates are included. The only other exhibit is Exhibit 104, the standard Inline XBRL cover-page data file. All remaining content—registration details, securities listing, emerging-growth-company status, and officer signature—matches routine SEC formatting.
Key takeaway for investors: today’s 8-K serves as a procedural notice that the Q1 2025 results press release is now available. Investors must review Exhibit 99.1 to assess the actual performance metrics and forward-looking commentary.